← Eichor
Condition: Pancreas Cancer Metastatic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pancreas Cancer Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Phase 3 · 2 location(s) · Shanghai Yizhong Pharmaceutical Co., Ltd. · NCT06752811Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metasta
Phase 2 · 2 location(s) · Medical University of South Carolina · NCT07076212DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Phase 2 · 5 location(s) · Hopital Foch · NCT06757244Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Phase N/A · 1 location(s) · University of Missouri-Columbia · NCT02838836Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
Phase 2 · 8 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT05065801A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor
Phase 2 · 31 location(s) · Allist Pharmaceuticals, Inc. · NCT06008288A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3 · 15 location(s) · SOFIE · NCT07217717A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Phase 2 · 13 location(s) · Belgian Group of Digestive Oncology · NCT05472259Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX
NA · 1 location(s) · Laval University · NCT06349278Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940Olaparib in PALB2 Advanced Pancreatic Cancer
Phase 2 · 1 location(s) · Azienda Ospedaliero-Universitaria di Modena · NCT06078787A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
Phase N/A · 1 location(s) · Institut Paoli-Calmettes · NCT07664891This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
NA · 7 location(s) · Institut Curie · NCT05475366A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
NA · 1 location(s) · Centre Leon Berard · NCT05380414Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT07214298CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06937567Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.